Abstract 580P
Background
Primary tumor location (PTL) is a well-established prognostic factor in stage III and IV colorectal cancer (CRC), with right-sided CRC (RSCC) showing a worse prognosis compared to left-sided CRC (LSCC). However, the impact of PTL on stage II CRC remains uncertain. One explanation for these inconsistencies is the potential confounding effect of molecular biomarkers, such as MMR status. Therefore, there is a need to elucidate the prognostic value of PTL, as well as the role of biomarkers in this effect.
Methods
This study utilized observational data from a retrospective cohort obtained from the Belgian Cancer Registry (BCR). The study population comprised all patients diagnosed with pathologically confirmed stage II CRC in Belgium from January 1st, 2015, to December 31st, 2016 (n= 3,278). Information on PTL, demographics, pathologic T category (pT category), and molecular biomarkers (including MMR status, BRAF and KRAS mutations) was collected from the registry, along with vital status to calculate overall survival (OS). The primary aim of this study was to investigate the independent prognostic value of PTL in stage II CRC. Additionally, we assessed whether potential confounding factors, such as biomarkers and demographics, influenced the prognostic effect of PTL.
Results
In the univariate analysis, patients with stage II RSCC had a significantly worse OS compared to those with LSCC (including rectal cancer; p-value=0.0055 and excluding rectal cancer; p-value=0.0035). Higher age and pT4 were also significantly associated with worse OS. However, in the multivariable analysis, only gender, age, and pathologic T-stage were found to be significant predictors of OS. PTL was not a significant factor in multivariable analysis. Furthermore, biomarkers such as MMR-status, BRAF-, and KRAS mutations did not show a significant effect on OS in either analysis.
Conclusions
Our analysis led us to the conclusion that PTL is not an independent prognostic factor in stage II. Notably, we observed confounding effects between patient characteristics and the prognostic impact of PTL, such as older age at diagnosis and shorter OS in patients with RSCC. Furthermore, molecular biomarkers did not have a statistically significant effect on OS in stage II CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Antwerp.
Funding
Antwerp University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10